Skip to main content
All lobbying filings

ABBVIE, INC.

Lobbying for ABBVIE INC.

 Filing 4th Quarter - Report
4th Quarter (Oct 1 - Dec 31) 2025 · District of Columbia · House · Senate · $1,330,000.00 expenses · posted Jan 20, 2026

Official filing document

 Bills named in this filing 7
  • S 1040
    Drug Competition Enhancement Act
  • S 864
    HELP Copays Act
  • HR 4299
    Protecting Patient Access to Cancer and Complex Therapies Act
  • HR 5376
    Impacts and Outcomes for Health Career Training Act
  • HR 1328
    Supply Chain Security and Growth Act of 2025
  • HR 1990
    American Innovation and R&D Competitiveness Act of 2025
  • HR 1
    An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
 Lobbying activity 6
Copyright/Patent/Trademark

S.1040, Drug Competition Enhancement Act Patent litigation reform issues and issues related to post-grant proceedings at the USPTO Value of intellectual property

Health Issues

S. 864, HELP Copays Act H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act Drug cost and pricing policy issues Patient affordability issues Issues related to the 340B program Issues related to data privacy Issues related to Hepatitis C elimination

Medicare/Medicaid

Public Law 117-169 (formerly known as H.R. 5376, Inflation Reduction Act) Implementation regarding Medicare Part D drug negotiation program Policy Proposals related to Medicare Part D and patient cost-sharing Department of Health and Human Services (HHS) drug policy issues and regulatory policy issues Issues related to HCV treatment Issues related to Parkinsons pharmaceutical innovation

Taxation/Internal Revenue Code

H.R. 1328, Supply Chain Security and Growth Act of 2025 H.R. 1990, American Innovation and R&D Competitiveness Act of 2025 Public Law No: 119-21 (formerly known as H.R. 1, One Big Beautiful Bill Act) Implementation Public Law 115-97 (formerly known as H.R. 1, Tax Cuts and Jobs Act) Implementation Policy proposals relating to economic activity in Puerto Rico International tax issues, including OECD digital taxation work program

Labor Issues/Antitrust/Workplace

Issues related to antitrust and competition policy

Trade (domestic/foreign)

Issues related to pharmaceutical tariffs and unfair trade practices

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.

Report a problem